TRAW Form 4: Director receives 11,530 options, 1-year vest
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Traws Pharma, Inc. (TRAW) filed a Form 4 disclosing a director stock option grant. On 10/12/2025, the reporting person acquired 11,530 stock options at a $3.01 exercise price. The options vest 100% on the first anniversary of the grant date and expire on 10/12/2035. Following the transaction, 11,530 derivative securities were beneficially owned on a direct basis.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
CAUTREELS WERNER
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to purchase) | 11,530 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to purchase) — 11,530 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did TRAW disclose in this Form 4?
A director was granted 11,530 stock options on 10/12/2025 at an exercise price of $3.01.
When do the TRAW options vest and expire?
They vest 100% on the first anniversary of the grant date (10/12/2026) and expire on 10/12/2035.
What is the ownership form after the transaction?
The filing lists 11,530 derivative securities beneficially owned on a direct basis.
What is the security type reported for TRAW?
A Stock Option (right to purchase) for underlying Common Stock.
Who is the reporting person on this TRAW Form 4?
The signature block shows /s/ Werner Cautreels dated 10/15/2025.
Was a Rule 10b5-1(c) plan indicated?
The form includes the checkbox reference, but the excerpt does not indicate it was checked.